コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 tase 1, which mediates the first step in the urea cycle.
2 rved enzyme in arginine biosynthesis and the urea cycle.
3 ornithine in the presence of arginase in the urea cycle.
4 into various intermediate metabolites of the urea cycle.
5 ut life to eliminate excess nitrogen via the urea cycle.
6 essential hepatic enzyme that initiates the urea cycle.
7 which controls the rate-limiting step of the urea cycle.
8 y of different enzymatic deficiencies of the urea cycle.
9 se phosphate pathway, and most or all of the urea cycle.
10 n developing embryos, thus avoiding a futile urea cycle.
11 alyzes the initial rate-limiting step of the urea cycle.
12 arginine in the final cytosolic step of the urea cycle.
13 oneogenesis, amino acid homeostasis, and the urea cycle.
14 defect in metabolic pathways, including the urea cycle.
15 by loss of arginine biosynthesis through the urea cycle.
16 BPD group were linked with alteration of the urea cycle.
17 acid metabolism with mild impairment of the urea cycle.
18 involved in the release of auxin and in the urea cycle.
19 athway that clarifies the role of the diatom urea cycle.
20 e mitochondrial fatty acid oxidation and the urea cycle.
21 itted reaction and rate-limiting step in the urea cycle.
22 n pathway and the recently discovered diatom urea cycle.
23 ycles are linked directly with the ornithine-urea cycle.
24 ramitochondrial, rate-limiting enzyme in the urea cycle.
25 vealed alterations in beta-oxidation and the urea cycle.
26 ks, such as the tricarboxylic acid (TCA) and urea cycles.
27 reactions in the tricarboxylic acid and the urea cycles.
29 tamine ratio is a sensitive index of in vivo urea cycle activity and correlates with clinical severit
31 compromised citric acid cycle flux, enhanced urea cycle activity, and increased amino acid catabolism
33 nge of nitrogenous compounds, and a complete urea cycle, all attributes that allow diatoms to prosper
34 Significant pathways included metabolism of urea cycle/amino group, alanine and aspartate, aspartate
35 aled that dysregulation of the mitochondrial urea cycle and a nucleotide imbalance were associated wi
36 nformation regarding roles and regulation of urea cycle and arginine metabolic enzymes in liver and o
37 turbations in intermediate metabolism in the urea cycle and aspartate-glutamate pathways disrupting m
39 en, Helicobacter pylori, also has a complete urea cycle and contains the rocF gene encoding arginase
40 present in the liver, is a key enzyme of the urea cycle and eliminates excess ammonia through the exc
41 oyl-phosphate synthetase I (CPSI, related to urea cycle and endogenous nitric oxide production) and c
43 of mutant cells highlighted purine, arginine/urea cycle and glutamate metabolisms as the most consist
47 demonstrates enhanced nitrogen flux into the urea cycle and infusion of (15)N-arginine shows that Arg
50 ses in sphingolipids, indicate that both the urea cycle and nitric oxide pathways are dysregulated at
53 glutamine from cells required to sustain the urea cycle and the glutamine-glutamate cycle that regene
54 ty acids, dipeptides, and metabolites of the urea cycle and xanthine, steroid, and glutathione metabo
56 ct changes in amino acid serum profiles, the urea cycle, and glycolysis, and attribute the difference
57 he detoxification of ammonia by means of the urea cycle, and in the synthesis of nitric oxide (NO).
59 d to the metabolism of steroids, bile acids, urea cycle, and long-chain polyunsaturated fatty acids.
60 in arginase 1 (ARG1), the final step of the urea cycle, and results biochemically in hyperargininemi
61 yll components, nitrate assimilation and the urea cycle, and synthesis of carbohydrate storage compou
63 amides, tryptophan, phospholipids, Krebs and urea cycles, and revealed kidney dysfunction biomarkers.
64 reveals how the enzymes associated with the urea cycle are expressed to ensure proper mass flow of t
65 d ammonia levels due to dysregulation of the urea cycle are known to cause neurologic impairment.
66 indicate that intermediates in the ornithine-urea cycle are particularly depleted and that both the t
69 an important role in the regulation of extra-urea cycle arginine metabolism by modulating cellular ar
70 ced modulation of hepatic metabolism and the urea cycle as an endogenous mechanism of immunoregulatio
71 egulation of its main metabolic pathway, the urea cycle, as reflected by down-regulation of urea cycl
72 abnormalities in neurotransmitter signaling, urea cycle, aspartate-glutamate metabolism, and glutathi
73 of enzymes related to fatty acid metabolism, urea cycle, cell replication, and mitochondrial function
76 Plasma amino acid analysis suggestive of a urea cycle defect and initiation of a treatment with lac
77 chieved stable therapeutic protection in two urea cycle defect mouse models; a clinically conceivable
78 effect on the hyperammonemia suggesting the urea cycle defect was independent of the aspartate/malat
79 sh the relative contributions of the hepatic urea-cycle defect from those of the NO deficiency to the
81 this technology in the management of severe urea cycle defects could be as a bridging therapy while
82 hown to selectively impact tumors displaying urea cycle defects including a large fraction of hepatoc
83 A-VA deficiency should therefore be added to urea cycle defects, organic acidurias, and pyruvate carb
86 nic aciduria (ASA) is an autosomal recessive urea cycle disorder caused by deficiency of argininosucc
88 ewborn mice with a partial deficiency in the urea cycle disorder enzyme, ornithine transcarbamylase (
89 blish an in vitro liver disease model of the urea cycle disorder ornithine transcarbamylase deficienc
90 acetate/benzoate or sodium phenylbutyrate in urea cycle disorder patients has been associated with a
91 ne levels at birth, with negative results of urea cycle disorder testing at the time, along with left
92 type I (CTLN1, OMIM# 215700) is an inherited urea cycle disorder that is caused by an argininosuccina
93 enylbutyrate is a drug used in patients with urea cycle disorder to elicit alternative pathways for n
96 iciency (OTCD, OMIM 311250), the most common urea cycle disorder, results in impaired synthesis of ci
98 cinic aciduria (ASA), the second most common urea-cycle disorder, and leads to deficiency of both ure
99 amylase deficiency (OTCD) is the most common urea-cycle disorder, characterized by hyperammonemia and
100 w that ASA, in addition to being a classical urea-cycle disorder, is also a model of congenital human
103 id (PBA), which is approved for treatment of urea cycle disorders (UCDs) as sodium phenylbutyrate (Na
105 Cells (HepaStem) in pediatric patients with urea cycle disorders (UCDs) or Crigler-Najjar (CN) syndr
106 mended long-term therapy of individuals with urea cycle disorders (UCDs), involve the risk of iatroge
107 tyrate is under development for treatment of urea cycle disorders (UCDs), rare inherited metabolic di
108 butyrate (Buphenyl(R)), a drug used to treat urea cycle disorders and currently in clinical trials fo
109 id butyrate and is approved for treatment of urea cycle disorders and progressive familial intrahepat
110 ying neurological dysfunction that occurs in urea cycle disorders and the only to examine arginase de
112 7 individuals longitudinally followed by the Urea Cycle Disorders Consortium (UCDC) and the European
113 in a natural history study conducted by the Urea Cycle Disorders Consortium, we found that 97% of pl
115 eticulous metabolic control in children with urea cycle disorders, because even mildly symptomatic su
116 for reducing plasma ammonia and glutamine in urea cycle disorders, can suppress both proinflammatory
117 um phenylacetate (NaPA), a drug approved for urea cycle disorders, in inhibiting the disease process
118 ug Administration-approved nontoxic drug for urea cycle disorders, in treating the disease process of
120 or IEMs (including glutaric aciduria type I, urea cycle disorders, mitochondrial disorders, and lysos
122 nd Drug Administration-approved drug against urea cycle disorders, upregulates Tregs and protects mic
124 mmonul, Ucyclyd Pharma) in 299 patients with urea-cycle disorders in whom there were 1181 episodes of
126 ctly regulates OTC activity and promotes the urea cycle during CR, and the results suggest that under
128 of specific enzymes in fatty acid oxidation, urea cycle, electron transport, and anti-oxidant pathway
129 rising finding that CPSase III and all other urea cycle enzyme activities are present in muscle of th
130 ions of the relationship between the hepatic urea cycle enzyme activities, the flux of (15)N-labeled
131 ent model was associated with restoration of urea cycle enzyme activity and function, reduced hepatic
140 tency of ornithine transcarbamylase (OTC), a urea cycle enzyme for which loss of catalytic activity c
142 ea cycle, as reflected by down-regulation of urea cycle enzyme protein expression and accumulation of
143 tion of argininosuccinate synthase (ASS1), a urea cycle enzyme suppressed in primary ccRCC, as a cruc
144 caused by deficiency of arginase 1 (ARG1), a urea cycle enzyme that converts arginine to ornithine.
151 The main aim was to evaluate changes in urea cycle enzymes in NAFLD patients and in two preclini
153 reduction in the expression and activity of urea cycle enzymes resulting in hyperammonemia, evidence
155 h the reported "channeling" of substrates by urea cycle enzymes, we hypothesize that the Arg/Cit cycl
158 ified by hepatic GS and approximately 35% by urea-cycle enzymes, while approximately 30% is not clear
162 n enzyme, catalyzing the initial step of the urea cycle for ammonia detoxification and disposal.
166 zone-specific functions associated with the urea cycle, glutathione synthesis and glutamate synthesi
170 that interleukin-17 (IL-17) re-programs the urea cycle in keratinocytes increasing polyamines that s
174 he genetically predetermined capacity of the urea cycle--in particular, the efficiency of carbamoyl-p
175 s and potentially neurotoxic ammonia via the urea cycle, including use of only free ammonia as a nitr
176 ting hypercatabolism and upregulation of the urea cycle independent of impaired renal clearance of ni
178 metabolites remain unchanged from rest; but urea cycle intermediates are increased, likely attributa
179 ted metabolites are generated from ornithine-urea cycle intermediates by the products of genes latera
180 production; (4) increased hepatic and renal urea cycle intermediates suggesting hypercatabolism and
181 athione metabolism) and nitrogen metabolism (urea cycle intermediates) accumulated until the end of t
182 ntrols. A panel of 12 metabolites, including urea cycle intermediates, aromatic amino acids and quino
188 tagenome was characterized by changes in the urea cycle, L-citrulline biosynthesis and creatinine deg
189 volved in translation, DNA synthesis and the urea cycle like translation initiation factor IF-2, 50S
190 t (Oncorhynchus mykiss), suggesting that the urea cycle may play a physiological role in early develo
191 and identified changes in purine salvage and urea cycle metabolism that may help to limit fumarate ac
192 e model of citrullinemia, an inborn error of urea-cycle metabolism characterized by deficiency of arg
193 ficantly associated with decreased levels of urea cycle metabolites and increased plasma glycine leve
195 ines; rho = 0.198, p = 0.017), and factor 8 (urea cycle metabolites; rho = - 0.239, p = 4 x 10(-3)),
196 m (spermidine: higher in AD, p = 0.004); (4) urea cycle (N-acetyl glutamate: lower in AD, p < 0.001);
197 expression of several enzymes present in the urea cycle occurs also in many other tissues, where thes
198 use, a model of the X-linked disorder of the urea cycle, ornithine carbamoyltransferase deficiency (O
201 zymes involved in the tricarboxylic acid and urea cycles, oxidative phosphorylation, as well as react
203 activity in liver of the first enzyme in the urea cycle pathway, carbamoyl-phosphate synthetase III (
205 ontrol subjects (ratio = 0.42 +/- 0.06) from urea cycle patients with late (0.17 +/- 0.03) and neonat
207 genes including those of albumin synthesis, urea cycle, phase I and II metabolic enzymes, and clotti
209 FXR-knockout mice had reduced expression of urea cycle proteins, and accumulated precursors of ureag
210 metabolism: carbamoylphosphate synthetase 1 (urea cycle), pyruvate carboxylase (anaplerosis, gluconeo
211 has been reported that the activities of the urea cycle-related enzymes ornithine carbamoyltransferas
212 s suggest that glycine metabolism and/or the urea cycle represent potentially novel sex-specific mech
213 vivo rates of total body urea synthesis and urea cycle-specific nitrogen flux would correlate with b
214 a variety of related pathways including the urea cycle, TCA cycle, gluconeogenesis, and phosphatidyl
217 yzes the entry and rate-limiting step in the urea cycle, the pathway by which mammals detoxify ammoni
220 d whose expression, similar to that of other urea cycle (UC) components, was high in liver and varied
222 d H2/CO2 (compared to fructose) point to the urea cycle, uptake and degradation of peptides and amino
224 show that the exosymbiont-derived ornithine-urea cycle, which is similar to that of metazoans but is